Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kodiak Sciences Inc.

https://kodiak.com/

Latest From Kodiak Sciences Inc.

Kodiak’s KSI-301 Has Narrower Path Forward After Phase II/III Failure In Wet AMD

Monthly dosing remains a possibility in wet age-related macular degeneration, though diabetic macular edema and retinal vein occlusion look more promising.

Ophthalmic Business Strategies

Five Pivotal Trial Read-Outs To Look Out For In Early 2022

Five notable studies are expected to report top-line data in the first quarter. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the major catalysts likely to kick off the year, including in heart failure and wet AMD.

Clinical Trials Companies

Adverum Faces Rocky Road As It Switches Gears From DME To Wet AMD

Adverum said it would cease developing ADVM-022 for DME and focus on wet AMD, but the adverse events that prompted the shift could invite further scrutiny in an already competitive market.

Clinical Trials Gene Therapy

Finance Watch: Olema IPO Raises $209m To Advance OPI-1250 For Breast Cancer

Olema launched this year’s 75th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Oligasis LLC
UsernamePublicRestriction

Register